[go: up one dir, main page]

EA201071068A1 - Антитела к tyrp1 - Google Patents

Антитела к tyrp1

Info

Publication number
EA201071068A1
EA201071068A1 EA201071068A EA201071068A EA201071068A1 EA 201071068 A1 EA201071068 A1 EA 201071068A1 EA 201071068 A EA201071068 A EA 201071068A EA 201071068 A EA201071068 A EA 201071068A EA 201071068 A1 EA201071068 A1 EA 201071068A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tyrp1
antibodies
present
provides
treating
Prior art date
Application number
EA201071068A
Other languages
English (en)
Other versions
EA019517B1 (ru
Inventor
Сяоцян Кан
Пол Дж. Балдерес
Original Assignee
Имклоун Элэлси
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40790741&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201071068(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Имклоун Элэлси filed Critical Имклоун Элэлси
Publication of EA201071068A1 publication Critical patent/EA201071068A1/ru
Publication of EA019517B1 publication Critical patent/EA019517B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Согласно настоящему изобретению предложены полностью человеческие антитела и химерные антитела, которые связываются с антигеном TYRP1 человека с аффинностью, сравнимой или выше чем для ТА99, антитело мыши, специфичное к TYRP1. Согласно настоящему изобретению также предложены полинуклеиновые кислоты и клетки-хозяева, кодирующие и экспрессирующие указанные антитела. Согласно настоящему изобретению также предложены способы изменения активности TYRP1, лечения роста раковых клеток, а также лечения злокачественной меланомы у животных путем введения эффективного количества антитела, самостоятельно или в комбинации с противораковым агентом или лечением.
EA201071068A 2008-03-12 2009-03-11 Антитела к tyrp1 и их применение EA019517B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6919908P 2008-03-12 2008-03-12
PCT/US2009/036739 WO2009114585A1 (en) 2008-03-12 2009-03-11 Anti-tyrp1 antibodies

Publications (2)

Publication Number Publication Date
EA201071068A1 true EA201071068A1 (ru) 2011-04-29
EA019517B1 EA019517B1 (ru) 2014-04-30

Family

ID=40790741

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071068A EA019517B1 (ru) 2008-03-12 2009-03-11 Антитела к tyrp1 и их применение

Country Status (19)

Country Link
US (1) US7951370B2 (ru)
EP (1) EP2268672A1 (ru)
JP (1) JP2011516041A (ru)
KR (1) KR101203777B1 (ru)
CN (1) CN101970500B (ru)
AR (1) AR070821A1 (ru)
AU (1) AU2009222998B2 (ru)
BR (1) BRPI0909633A2 (ru)
CA (1) CA2718289A1 (ru)
CL (1) CL2009000567A1 (ru)
EA (1) EA019517B1 (ru)
IL (1) IL207581A0 (ru)
MX (1) MX2010010021A (ru)
NZ (1) NZ587305A (ru)
PE (1) PE20091679A1 (ru)
TW (1) TWI384997B (ru)
UA (1) UA99339C2 (ru)
WO (1) WO2009114585A1 (ru)
ZA (1) ZA201006099B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2167540T3 (en) * 2007-06-29 2018-04-30 Hoffmann La Roche Heavy chain mutant leading to improved immunoglobulin production
RU2016135933A (ru) 2014-02-07 2018-03-15 Тон Вха Фарм. Ко., Лтд. Композиция для противоракового вспомогательного лекарственного средства, содержащая средство, индуцирующее экспрессию rip3, в качестве активного ингредиента, способ скрининга противоракового вспомогательного лекарственного средства, повышающего чувствительность к противораковому лекарственному средству путем стимуляции экспрессии rip3, и способ контроля чувствительности к противораковому лекарственному средству
EP3233907B1 (en) 2014-12-19 2021-03-03 Genmab A/S Rodent bispecific heterodimeric proteins
RU2630647C1 (ru) * 2016-05-27 2017-09-11 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
GB201613167D0 (en) 2016-07-29 2016-09-14 Univ Southampton Cancer and b-cell related disease therapy
WO2018075586A1 (en) * 2016-10-18 2018-04-26 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins targeting melanoma differentiation antigens and uses thereof
EP3638294A4 (en) * 2017-06-14 2021-01-06 Adicet Bio Inc. Antibodies capable of binding hla-a2/tyrd in an hla restricted manner and uses thereof
RU2687609C1 (ru) * 2018-05-30 2019-05-15 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Гуманизированное антитело к конформационному эпитопу сз компонента комплемента человека
MX2021003636A (es) 2018-09-27 2021-07-21 Autolus Ltd Receptor antigenico quimerico.
JP7440509B2 (ja) * 2018-11-09 2024-02-28 ベス イスラエル デアコネス メディカル センター Ｃｄｃｐ１－標的化療法
CR20210330A (es) * 2018-12-21 2021-07-20 Hoffmann La Roche ANTICUERPOS QUE SE UNEN A CD3 (Divisional 2021-0325)
WO2021046432A1 (en) * 2019-09-06 2021-03-11 The Regents Of The University Of California Chimeric antigen receptors and related methods and compositions for the treatment of cancer
WO2023094569A1 (en) * 2021-11-26 2023-06-01 F. Hoffmann-La Roche Ag Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
WO2025104289A1 (en) 2023-11-17 2025-05-22 Medincell S.A. Antineoplastic combinations
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4798790A (en) * 1985-07-18 1989-01-17 Sloan-Kettering Institute Monoclonal antibody specific for a pigmentation associated antigen
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
IL89489A0 (en) 1988-03-09 1989-09-10 Hybritech Inc Chimeric antibodies directed against human carcinoembryonic antigen
AU631545B2 (en) 1988-04-15 1992-12-03 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
JP3105898B2 (ja) 1988-04-16 2000-11-06 セルテック リミテッド 組換えｄｎａタンパクの製造方法
IE20000918A1 (en) 1990-03-22 2001-05-30 Sloan Kettering Inst Cancer GP75 As a Tumor Vaccine for Melanoma
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
WO1996040249A1 (en) 1995-06-07 1996-12-19 Sloan-Kettering Institute For Cancer Research Therapeutic uses of ta99
US5840839A (en) 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
KR20010015818A (ko) * 1997-11-14 2001-02-26 유로-셀티큐 에스.에이. 합성된 가변성 부분 및 변형 특이성을 가지는면역글로불린 분자
AU7485301A (en) * 2000-05-16 2001-11-26 Bolder Biotechnology Inc Methods for refolding proteins containing free cysteine residues
WO2006047340A2 (en) * 2004-10-22 2006-05-04 Amgen Inc. Methods for refolding of recombinant antibodies

Also Published As

Publication number Publication date
CN101970500B (zh) 2013-08-14
WO2009114585A1 (en) 2009-09-17
BRPI0909633A2 (pt) 2015-09-22
MX2010010021A (es) 2011-02-15
US7951370B2 (en) 2011-05-31
ZA201006099B (en) 2012-01-25
IL207581A0 (en) 2010-12-30
EP2268672A1 (en) 2011-01-05
TW200944232A (en) 2009-11-01
AR070821A1 (es) 2010-05-05
AU2009222998A1 (en) 2009-09-17
CA2718289A1 (en) 2009-09-17
TWI384997B (zh) 2013-02-11
AU2009222998B2 (en) 2013-05-23
NZ587305A (en) 2012-05-25
UA99339C2 (ru) 2012-08-10
JP2011516041A (ja) 2011-05-26
PE20091679A1 (es) 2009-11-04
EA019517B1 (ru) 2014-04-30
US20090232823A1 (en) 2009-09-17
KR20100113631A (ko) 2010-10-21
KR101203777B1 (ko) 2012-11-21
CL2009000567A1 (es) 2010-02-26
CN101970500A (zh) 2011-02-09

Similar Documents

Publication Publication Date Title
EA201071068A1 (ru) Антитела к tyrp1
JOP20200237A1 (ar) الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
PH12015500084A1 (en) Rspo3 binding agents and uses thereof
MX2015013194A (es) Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 humanizado.
MX349198B (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
MX2018010776A (es) Moleculas de union de antigeno multiespecificas y usos de las mismas.
UA108912C2 (ru) БЕЛОК, КОТОРЫЙ СВЯЗЫВАЕТ TNF-a
EA201791393A3 (ru) Антитела к erbb3 и их применение
DOP2013000045A (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
TR201905909T4 (tr) Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları.
EA201492137A1 (ru) Антитела к cd33 и их применение в лечении рака
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
PH12013500826A1 (en) Means and methods for treating dlbcl
EA201390575A1 (ru) Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты
MX2010009190A (es) Anticuerpos anti-c5ar humanizados.
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
MX2019000094A (es) Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos.
EA201591131A1 (ru) Днк-конструкции антитела и способ их применения
EP4530630A3 (en) Monoclonal antibodies and methods of use
NZ701370A (en) Il-6 binding molecules
EA201391423A1 (ru) Антитела к ассоциированному с почками антигену 1 и их антигенсвязывающие фрагменты
EA201992513A1 (ru) Способ лечения рака груди
CU20130025A7 (es) Anticuerpos anti-ox40 y métodos de uso de los mismos

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU